Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.69)
# 771
Out of 5,128 analysts
108
Total ratings
49.23%
Success rate
9.14%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $216 → $230 | $176.00 | +30.68% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.89 | +111.64% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $8.54 | +28.81% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $4.30 | +39.53% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $2.41 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $503.69 | +4.23% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $61.31 | +46.79% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $484.15 | -0.86% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $56.72 | -3.03% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $124.35 | -35.67% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $14.09 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $812.27 | +24.96% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $341.64 | +18.55% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $422.50 | -47.93% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $16.02 | -37.58% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.85 | +11.11% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $57.99 | +24.16% | 1 | Apr 13, 2023 |
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $176.00
Upside: +30.68%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.89
Upside: +111.64%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $8.54
Upside: +28.81%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $4.30
Upside: +39.53%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.41
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $503.69
Upside: +4.23%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $61.31
Upside: +46.79%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $484.15
Upside: -0.86%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $56.72
Upside: -3.03%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $124.35
Upside: -35.67%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $14.09
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $812.27
Upside: +24.96%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $341.64
Upside: +18.55%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $422.50
Upside: -47.93%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $16.02
Upside: -37.58%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.85
Upside: +11.11%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $57.99
Upside: +24.16%